In a bid to achieve 20% growth year-on-year, Natco Pharma is planning to launch around 8-10 new products in domestic branded formulations segment during FY18. The Hyderabad-based drug firm is also planning to maintain its leadership position in oncology and gastro hepatology segment during the year as part of its short-term growth plan.
Moreover, the company is looking at gaining traction in the newly launched cardiology and diabetology (CnD) division. The company is also planning to expand its Hepatitis-C product portfolio during the year.
